The study of the lipid membrane charge effect when creating liposomes with oxaliplatin

Authors

  • O. V. Stadnichenko National Technical University “Kharkiv Polytechnic Institute”, Ukraine
  • Yu. M. Krasnopolsky National Technical University “Kharkiv Polytechnic Institute”, Ukraine
  • T. G. Yarnykh National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/nphj.16.2133

Keywords:

liposomes, oxaliplatin, lipid bilayer, high pressure homogenization

Abstract

The fight against cancer diseases is one of the most urgent problems of modern pharmacy. One of the basic standards of treatment is surgery in order to remove tumours with chemotherapeutic agents for suppression of disease manifestations. One of the ways for reducing toxicity of cytostatics is their incorporation into liposomes – nanoparticles composed of the lipid bilayer surrounding the internal cavity with the aqueous medium. Oxaliplatin is a platinum-containing chemotherapeutic agent of the 3-rd generation used as monotherapy or in combination with other drugs. When creating liposomal drugs the beginning of the work is associated with the study of the composition of the lipid membrane. The aim of the work is to study the effect of the lipid membrane charge when creating liposomes with oxaliplatin. Four types of differently charged lipid membranes for liposomal oxaliplatin formulation have been tested. Liposomes were formed by the lipid layer method with further high pressure homogenization. As a criterion the encapsulation degree was used. The highest encapsulation degree has been determined in negatively charged liposomes with the lipid membrane modified by dipalmitoyl phosphatidylglycerol (DPPG).

References

Стадниченко А.В., Краснопольский Ю.М., Швец В.И. // Тонкие хим. технол. – 2015. – Т. 10, №1. – С. 60-65.

Шахмаев А.Е., Кацай А.Г., Стадниченко А.В. и др. // Ремедиум. – 2015. – №12. – С. 26-59.

DeAngelis L.M., Posner J.B. // Neurol. Complications of Cancer. 2-nd ed. Contemporary Neurol. Series. – Oxford University Press, Oxford, 2009. – P. 447-510.

Dranov A.L., Dudnichenko A.S., Mezin I.A. et al. // Bull. of Experim. Biol. and Medicine. – 1996. – Vol. 121, №1. – P. 77-80.

Kohler B.A., Sherman R.L., Howlader N. et al. // J. Natl. Cancer Inst. – 2015. – Vol. 5, №2. – 107 p.

Lipp H.P., Bokemeyer C., Hartmann J.T., Stanley A. // Side Effects of Drugs Annual. – 2003. – Vol. 26. – P. 490-511.

Shamudheen M., Mohammad R., Byung L. et al. // Experim. Hematol. & Oncol. – 2012. – Vol. 10, №1. – P. 19-23.

Strebhardt K., Ullrich A. // Nat. Rev. Cancer. – 2008. – Vol. 8, №6. – P. 473-480.

Downloads

Published

2016-12-21

Issue

No. 4(88) (2016)

Section

Technology of Medicines

License

Copyright (c) 2016 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).